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Immunoglobulin light chain amyloidosis and the kidney. Amy- ciated with a plasma cell dyscrasia and immunoglobulin
loidosis (AL) is a common cause of nephrotic syndrome in non- light chain [9]. All other forms are ultrastructurally re-
diabetic, nonhypertensive adults. All adult patients with neph- lated to proteins that are chemically unrelated to the im-rotic syndrome should have immunofixation of serum and urine
munoglobulin light chain molecule [10]. AL fibrils can beas a screen. The finding of a monoclonal protein, particularly
of lambda type, should lead to a subcutaneous fat aspirate or produced in vitro by digesting purified monoclonal light
bone marrow biopsy to search for amyloid deposits. When the chains with pepsin [11]. The immunoglobulin light chain
result of either test is positive, a kidney biopsy is unnecessary. is thought to have an aberrant amino acid sequence. Spe-The prognosis of patients who have renal amyloidosis depends
cific light chains appear to have amino acid sequences thaton the concentration of serum creatinine at presentation and
whether an echocardiographic evaluation demonstrates infil- predispose them to form amyloid [12]. In normal adults,
trative cardiomyopathy. Most therapies are directed against the immunoglobulins with kappa light chains outnumber those
plasma cell dyscrasia present in all patients with AL and can in- with lambda light chains by a ratio of 2:1. In amyloidosisclude melphalan and prednisone, high-dose dexamethasone,
the ratio of kappa:lambda light chains is 1:3, suggestingand, most recently, peripheral blood stem cell transplantation.
that lambda immunoglobulin light chains are predisposed
to form the beta-pleated sheet ultrastructure associated
Systemic AL amyloidosis, also known as immunoglob- with amyloid [13]. The VI appears to be uniquely predis-
ulin light chain and primary amyloidosis, is associated with posed to form amyloid [14].
an underlying monoclonal plasma cell dyscrasia [1]. In AL, Because AL is a plasma cell dyscrasia, it is not surprising
a clonal population of plasma cells produces a mono- that some patients with AL have overt associated multi-
clonal light chain or fragment thereof. The immunoglob- ple myeloma where the light chain-secreting plasma cells
ulin light chain fragment forms a beta-pleated sheet pro- are a part of a frankly malignant clone [15]. These rare
tofilament that ultimately polymerizes into the complete patients may have lytic bone disease and anemia due to
amyloid fibril [2]. Amyloid fibrils are relatively nonbio- plasma cell replacement of the bone marrow. Eighteen
degradable [3]. Accumulation of the fibril protein even- percent of patients with AL have a bone marrow speci-
tually results in organ dysfunction and death. Involve-
men with greater than 20% plasma cells [16]. If multiplement of the kidneys is the most common clinical problem
myeloma is not present at the diagnosis of AL, it is un-in AL and is present in one-third of patients at diagnosis
likely to develop [17]. The median age of patients with[4]. At postmortem examination, most AL patients have
AL seen at the Mayo Clinic is 62 years. The incidenceevidence of amyloid deposition within the kidney [5].
of AL is 8 per million per year and has remained stableAll forms of amyloid are characterized by positive stain-
during the past four decades [18]. Two-thirds of the pa-ing with Congo red [6]. When viewed under polarized
tients with AL are men, and only 1% is younger than agelight, amyloid deposits demonstrate apple green birefrin-
40 years. The most common presenting symptoms of pa-gence. Under the electron microscope, all forms of amy-
tients who have AL are fatigue and weight loss. Light-loid are fibrillar, usually rigid, and nonbranching [7].
headedness is also a common complaint and occurs in pa-Amyloid fibrils are insoluble in saline. They can be puri-
tients with nephrotic syndrome due to significant plasmafied because they form a suspension in distilled water [8].
volume contraction [19, 20]. In patients with cardiac in-There are many types of amyloid, but only AL is asso-
volvement, the reduced stroke volume due to diastolic
dysfunction produces systolic hypotension [21]. Hypo-Key words: amyloidosis, multiple myeloma, nephrotic syndrome, stem
cell transplantation. tension may also occur as a consequence of autonomic
failure [22].
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ical findings are generally nonspecific and do not consis- cutaneous fat [33], salivary glands [34], skin, and rec-
tum [31, 35].tently raise suspicion of amyloidosis.
CLINICAL FEATURES OF RENAL AMYLOIDDIAGNOSING AMYLOIDOSIS
In AL, the most frequently affected organ is the kid-A clinician should suspect amyloidosis whenever a pa-
ney. Dysfunction of the kidney is the presenting problemtient presents with (1) nephrotic-range proteinuria with
in one-third to one-half of patients with amyloid [36].or without renal insufficiency, (2) congestive heart failure
Renal amyloid is found in 2.5% to 2.8% of all renalfrom restrictive cardiomyopathy [23], (3) hepatomegaly,
biopsy specimens [37]. In nondiabetic adults with ne-or (4) peripheral neuropathy. When a patient is seen with
phrotic syndrome, amyloidosis accounts for 12% of renalone of these four syndromes, immunofixation of the se-
biopsies [38]. Survival with renal amyloidosis dependsrum or urine is required [24]. Every patient with neph-
on the concentration of serum creatinine at presentation.rotic-range proteinuria must have immunofixation of the
Patients who present with a creatinine value less thanserum and of the urine performed, because the finding
1.3 mg/dL have a median survival of 25.6 months, whileof a monoclonal immunoglobulin light chain may often
those with an increased creatinine value have a medianobviate the need for a renal biopsy [25].
survival of 14.9 months (P 0.01). The amount of 24-hourProteinuria does not always equate with albuminuria,
urine protein excretion has no impact on survival; how-and free monoclonal light chains when present limit the
ever, the time from original diagnosis to the developmentdifferential diagnosis to cryoglobulinemia, amyloidosis,
of end-stage renal disease (ESRD) is less in patients withRandall type light chain deposition disease, and myeloma
higher amounts of protein excretion.cast nephropathy. All patients with AL have a clonal
Sixty percent of patients with amyloid excrete at leastpopulation of plasma cells or lymphoplasmacytic cells in
1 g per day of protein. Fewer than 5% have a urinarytheir bone marrow [26]. This finding is useful because
protein loss less than 150 mg/day. Most of the patients
approximately 11% of patients with AL do not have a
with little or no proteinuria have isolated amyloid periph-
detectable light chain by immunofixation of the serum eral neuropathy [39]. Approximately two-thirds have a de-
or urine, and the finding of a clonal population of plasma tectable monoclonal light chain in the urine and two-
cells in a patient with nephrotic-range proteinuria or re- thirds have a detectable monoclonal light chain in the
nal insufficiency should lead to a diagnostic evaluation serum. The higher the urinary protein loss, however, the
focused on AL. If one believes AL is likely and there is more likely it is to find a monoclonal light chain. In amy-
no monoclonal protein, one may choose to perform a bone loid patients excreting more than 1 g per day of urinary
marrow biopsy. Immunofixation of serum and urine is re- protein, 86% had a light chain in the urine.
quired because the monoclonal peaks in amyloid tend to When patients have progressively greater degrees of pro-
be small and frequently do not produce a spike detect- tein loss, the ratio of kappa:lambda light chains changes.
able with electrophoresis alone [27]. A third of patients In patients with nephrotic-range proteinuria the kappa:
with AL have only free light chains in the serum, which lambda ratio approaches 1:5 [40]. Patients with neph-
rarely produces a detectable peak and can be recognized rotic-range proteinuria are fivefold more likely to have
only by immunofixation [28]. When nephrotic-range pro- a monoclonal lambda light chain. The median urinary
teinuria is present, the nonselective proteinuria can fre- protein loss in patients who have kappa amyloidosis is
quently “bury” the small amounts of excreted monoclonal 1.09 g per day. Patients with a lambda protein in the
light chains. urine have a median urinary protein loss of 4.6 g per
All amyloid deposits contain serum amyloid P compo- day, suggesting that the lambda light chain predisposes
nent. Using iodine-labeled human serum amyloid P, whole to greater degrees of infiltration of the kidney. Median
body imaging can be performed with a gamma camera and survival in patients with urinary lambda light chain excre-
can demonstrate the anatomic distribution of amyloid de- tion is inferior compared with that of those who have
posits [29]. The plasma clearance of labeled P component either a kappa or no monoclonal protein in the urine: 1
is directly proportional to the total body amyloid load and 2.5 years, respectively. Surprisingly, renal insuffi-
[30]. The final diagnosis of amyloidosis rests on demon- ciency was not more prevalent in patients who had a
strating Congo red-positive deposits in tissues. Virtually monoclonal lambda as opposed to a kappa light chain
all patients with renal, cardiac, hepatic, and peripheral in the urine [40].
nerve amyloid have demonstrable deposits by biopsies One consequence of the nephrotic-range proteinuria
of the respective tissues [31]. In general, biopsies of these is profound serum hypoalbuminemia [41]. The loss of
viscera are not needed because the widespread nature albumin results in a reduced intravascular oncotic pres-
of amyloid permits the detection of deposits in less-inva- sure [42], which leads to fluid transudation into the extra-
cellular space with resultant edema. The edema generallysively sampled tissues such as the bone marrow [32], sub-
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requires the use of diuretics, which may in turn produce 2% of patients with amyloid develop renal involvement
increased volume contraction, progressive hypotension after presentation. Previously, patients with advanced
and reduced renal blood flow, thus causing the creatinine cardiac amyloid died within a year after diagnosis. With
concentration to rise [43]. In patients with severe ne- the advent of cardiac transplantation, we have seen sev-
phrotic syndrome, anasarca may develop. Diuretic man- eral recipients who subsequently developed nephrotic
agement is impractical in this situation, and many pa- syndrome. This led to renal transplantation in one pa-
tients are too ill for bilateral nephrectomy. Bilateral tient and peripheral blood stem cell transplantation in
catheter embolization of the renal arteries has been re- two others.
ported, with a reduction of urinary protein loss from 18 g The proteinuria in amyloidosis results from amyloid
to 0.5 g and a subsequent increase in total serum protein penetration of the glomerular basement membrane [51].
from 3.1 to 5.17 g/dL [44]. The adult Fanconi syndrome, renal vein thrombosis, and
The principal long-term complication of continuous retroperitoneal fibrosis have all been reported to be asso-
urinary protein loss is tubular damage that results in ciated with renal amyloidosis. Immunotactoid glomeru-
ESRD [45, 46]. The only predictors of which patients lopathy is another fibrillar disorder of the kidney that
ultimately go on to develop ESRD are the 24-hour urine potentially could be confused with AL. The fibrils of im-
protein loss and creatinine value at diagnosis. The me- munotactoid glomerulopathy are twice the width of typi-
dian time from diagnosis of AL nephrotic syndrome to cal amyloid fibrils [52]. Patients with immunotactoid glo-
the initiation of dialysis is 14 months. Median survival merulopathy never develop extrarenal disease, and the
for patients from the start of dialysis is 8 months. There deposits are not Congo red positive. No monoclonal pro-
is no survival difference for AL patients receiving hemo- tein is detected. Randall-type light chain nephropathy
dialysis or peritoneal dialysis. Sixteen patients with AL represents the deposition of nonamyloid immunoglobu-
received chronic dialysis after the onset of ESRD. Sur- lin light chains in a granular fashion in the kidney [53]. It
vival rate at one year was 68%, with no difference be- can produce nephrotic syndrome and renal insufficiency
tween hemodialysis and chronic ambulatory peritoneal [54]. Amyloid and light chain nephropathy have been
dialysis. Patients younger than age 45 years had a better
reported in the same patient [55]. Light chain nephropa-
survival. The most important extrarenal complications
thy never shows fibrillar or congophilic deposits unlessof amyloidosis were related to cardiac involvement (in-
the two diseases coexist in the same patient [54].cluding heart failure, rhythm disturbances, and refrac-
tory hypotension) and gastrointestinal tract involvement
manifested by malabsorption. The most common causes PROGNOSIS
of death result from extrarenal amyloid deposits in the The cause of death in most patients with amyloidosis is
heart, followed by the liver. Dialysis was regularly com- cardiac, either progressive cardiomyopathy with heart fail-
plicated by intradialytic hypotension [47]. ure or sudden death due to ventricular arrhythmia [56].
There is a poor correlation between the extent of amy-
Because an individual patient’s clinical outcome is highly
loid deposits seen on a kidney biopsy specimen and the
dependent on the extent of cardiac involvement, an echo-extent of proteinuria [5]. Even small amyloid deposits
cardiogram should be a routine part of the assessmenthave been associated with severe nephrotic syndrome
of patients with AL [57]. The presence of symptomatic[48]. Although it has been suggested that the kidneys
heart failure is the most powerful predictor of survivalare enlarged in amyloidosis, most patients with renal
[58]. The presence of exertional syncope is a powerful pre-amyloid have normal-sized kidneys by ultrasound [49].
dictor of sudden death [59]. The most significant echo-The urinary sediment in amyloidosis is usually bland,
cardiographic predictors of outcome appear to be theshowing only fat or fatty acid crystals. A cellular or in-
Doppler index of diastolic myocardial performance, ejec-flammatory sediment is generally not found. Of 118 pa-
tion fraction, and mitral deceleration time. Patients withtients with monoclonal gammopathies who underwent
a deceleration time of 150 ms or less on Doppler echocar-renal biopsy, 30% had AL. The mean time from diagno-
diography, indicating restrictive physiology, have a one-sis to dialysis in this study was 15 months; the median
year survival of 49% versus 92% in patients whose decel-survival was 24 months; and the main cause of death dur-
eration time is greater than 150 ms [60].ing the first year of dialysis was cardiac involvement with
In one study, the percentage of bone marrow plasmaamyloid. A trend to increased survival was noticed with
cells and the kappa-to-lambda ratio of plasma cells inchemotherapy, which appeared to slow progression to
the bone marrow were associated with survival. The boneESRD. Independent predictors of survival were age less
marrow plasma cell kappa-to-lambda ratio was an inde-than 70 years and serum creatinine and calcium concen-
pendent prognostic variable. Bone marrow plasma celltrations at presentation [50].
kappa-to-lambda ratio of less than 1:5 in lambda amyloidIf amyloid does not involve the kidney at presentation,
it is rare for it to occur during the follow-up period; only or kappa-to-lambda ratio of greater than 16:1 in kappa
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amyloid identified two groups with significant differences ous. Melphalan-based therapies carry the potential for
the development of late myelodysplasia or acute leuke-in overall survival [61].
mia [71]. Because these patients are often elderly, myelo-
dysplasia usually results in rapid death, and the median
THERAPY
survival from the onset of myelodysplasia is only 8 months.
In addition to the supportive therapies available for A myelodysplastic disorder develops in 6.5% of patients
patients with nephrotic syndrome [62], specific therapy exposed to melphalan. Melphalan, when given to patients
should be considered that is directed at the light chain- with amyloid, is given in a fashion identical to that for
producing clonal plasma cells. Patients with amyloidosis multiple myeloma. A standard dosage would be 0.15 mg/kg
who are treated with alkylating agent-based chemother- per day orally for seven consecutive days along with pred-
apy such as melphalan and prednisone have an improved nisone at 20 mg three to four times a day for the same
survival if they respond [63]. The median survival of 27 seven days. These cycles are generally repeated every
patients who responded to melphalan therapy was nearly six weeks, with the dose adjusted to produce a moderate
90 months compared with only one year for nonrespond- degree of midcycle leukopenia. In our experience, pa-
ers. The time to achieve a response in amyloidosis can tients presenting with a creatinine value3.0 mg/dL may
be as long as one year. This relates to the body’s relative stabilize, but they only rarely fulfill the criteria for a
inability to mobilize preexisting amyloid deposits. The response to therapy. Decisions regarding treatment in
majority of patients with AL do not survive long enough these patients need to be made on an individual basis.
to have an opportunity to respond. The actuarial survival Because the majority of patients (70%) do not respond
of all Mayo Clinic patients was 51% at one year, 16% to melphalan and prednisone chemotherapy, alternatives
at five years, and 4.7% at ten years [64]. All long-term need to be found. We have prior experience with alpha
survivors were treated with alkylating agent therapy. In tocopherol [72] and interferon- [73], and have found
14 patients the monoclonal protein disappeared from neither agent to be effective. High-dose dexamethasone
the serum or urine, implying that production of the amy- with interferon has been reported to be effective in pa-
loidogenic light chain was interrupted. tients with amyloidosis [74]. Dexamethasone is not leu-
The definition of a response in AL can be either organ kemogenic, and the toxicity tends to be transient and
based or hematologic. In the former, a response is de- reversible. In our hands, high-dose dexamethasone has
fined as a 50% reduction in urinary protein loss for pa- a response rate of only 15% and is used if there are no
tients with renal involvement in the absence of an in- other alternatives [75, 76]. The treatment of renal amy-
crease in creatinine concentration [65]. Organ response loid nephrotic syndrome with vincristine, doxorubicin, and
criteria also exist for patients with liver, cardiac, and dexamethasone has been reported; three of four patients
intestinal amyloidosis. The hematologic response criteria attained a partial response and continuing remission
are identical to those commonly used in the assessment after four to nine years [77]. The use of 4-iodo-4-deoxy-
of response in multiple myeloma patients treated with che- doxorubicin in the treatment of amyloidosis has been
motherapy. When assessing response in AL, both organ reported [78, 79]. It appears to be most effective for pa-
response and M protein response should be included. tients with soft tissue deposits and less effective for those
There are two prospective randomized studies that dem- with visceral amyloidosis. The drug is believed to act by
onstrate a survival advantage for patients treated with binding and dissolving amyloid deposits without exerting
melphalan and prednisone compared with colchicine a cytotoxic effect on bone marrow plasma cells [80].
alone [66, 67]. In these reports, the responses included Heart transplantation has been used for AL patients,
organ responses and hematologic responses. Even pa- and survivals of 69 and 118 months were reported [81, 82].
tients with symptomatic congestive heart failure can re- We have performed 14 cardiac transplantations for amy-
spond to melphalan and prednisone therapy. Three pa- loidosis. Patients are screened to exclude those who have
tients have been reported to have marked resolution of any evidence of extracardiac amyloidosis. Two patients
heart failure and evidence for remission of disease activ- have died of progressive cardiac amyloid and one of re-
ity [68]. The five-year survival of patients with cardiac jection. One patient in whom nephrotic syndrome devel-
amyloidosis is 5%. Virtually all long-term survivors have oped five years after transplantation received a renal
shown an objective response to chemotherapy [69]. transplant and is now alive 8-1/2 years after heart trans-
All patients with AL deserve a trial of therapy because plantation. Four patients have received subsequent stem
of the improved survival of responders. One patient sur- cell transplants in an effort to prevent recurrent amyloid
vived 21 years after biopsy-proven renal amyloidosis was postcardiac transplantation (abstract; McGregor et al,
reported. Initial therapy included chemotherapy fol- J Heart Lung Transplant 19:51, 2000). Renal transplanta-
lowed by dialysis and then a successful renal transplant, tion has been reported for the management of amy-
functioning ten years later with no evidence of recurrent loidosis, but the majority of the reported instances have
been in patients with AA amyloid, which has a more in-disease [70]. The treatment of amyloidosis is not innocu-
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dolent natural history. Since the data with regard to renal status, adequate creatinine value, and good cardiac func-
tion—severely limit the applicability of allogeneic trans-transplant in AL are inconsistent and the numbers are
small, it is impossible to draw conclusions regarding graft plant for amyloidosis.
Autologous peripheral blood stem cell transplantationsurvival and the development of extrarenal amyloid after
renal transplantation. The recurrence of amyloid in the has supplanted autologous bone marrow transplantation
in the management of malignant diseases because of thetransplanted kidney is well reported [83].
More intensive chemotherapy has been attempted. In ease of stem cell collection and the more rapid engraft-
ment achieved using peripheral blood stem cells versusa prospective study, 101 patients were randomized to
receive either melphalan and prednisone or the five-drug autologous bone marrow. The first reported case of an
autotransplant for amyloid was a 53-year-old woman whoregimen: vincristine, BCNU, melphalan, cyclophospha-
mide, and prednisone (VBMCP). No survival advantage died of cytomegalovirus pneumonia before day 100 [91].
Plasma cell clone-related sequences from the peripheralwas seen for the five-drug combination compared with
the two-drug combination [84]. blood stem cell product have been detected in DNA from
the peripheral blood in 8 of 10 amyloidosis patients atAmyloidosis is not a true neoplasm. The percentage
of plasma cells in the bone marrow typically does not diagnosis and from the apheresis product of 3 of 4 under-
going stem cell mobilization. Circulating monoclonalincrease over time and the size of the monoclonal protein
does not increase over time, as it does in multiple mye- plasma cells are present at diagnosis in 16% of patients
with AL [92, 93]. The clinical implications of re-infusingloma. Nonetheless, all therapies currently in use for amy-
loidosis were derived from regimens demonstrated to be clonal plasma cells at transplantation remain unknown.
The largest reported experience with stem cell trans-effective in the management of myeloma [37, 85]. In view
of the poor results achieved with standard chemotherapy plantation for AL is from the Boston University Medical
Center. Patients were mobilized by using growth factorand recognizing the higher complete response rates and
an improved survival demonstrated with the use of stem only, and stem cells were collected on the fifth day. Most
patients were conditioned with melphalan (200 mg/m2).cell transplantation for multiple myeloma [86], it was in-
Patients with advanced organ dysfunction or poor per-evitable that this technique would be applied to patients
formance status could be conditioned at reduced mel-with amyloidosis.
phalan doses (100 to 140 mg/m2). When the first 25 pa-
tients were reported, the group had a median age of 48
BONE MARROW OR PERIPHERAL BLOOD years, and 88% had a performance status of 1 or 2 (up
STEM CELL TRANSPLANTATION and about 50% of waking hours). No patient had con-
Patients who have a bone marrow transplantation for gestive heart failure, although 8 patients had echocardio-
hematologic malignancy generally have no visceral organ graphic evidence of amyloid. Seventeen of 25 patients
dysfunction. Most marrow or stem cell transplant pro- were alive at 24 months. Thirteen of 21 evaluable patients
grams require adequate cardiac and pulmonary function, had elimination of clonal plasma cells, and 11 of 17 had
good performance status, excellent hepatic function [87], improved amyloid-related organ involvement. There were
and good nutrition [88]. Unfortunately, most patients three relapses between 12 and 24 months. The best re-
with amyloidosis present with dysfunction of any or all of sults were seen in patients with renal involvement mani-
these organs. In amyloidosis, anemia is uncommon un- fested by proteinuria. Predictors of adverse survival in-
less there is associated renal insufficiency. The frequent cluded more than two major organ systems involved or
dysfunction of the heart, liver, kidney, and nerves in pa- predominant cardiac involvement. Acute leukemia sub-
tients with AL makes this a unique group compared with sequently developed in one patient. Two patients died
other patients undergoing transplantation. during or after stem cell collection before conditioning
Human lymphocyte antigen (HLA)-matched alloge- for transplant. Three of the 25 patients died before day
neic bone marrow transplantation has been performed 100 post-transplantation [94].
for AL. One patient with pretransplantation renal in- When the Boston experience was updated to 102 pa-
volvement manifested by urinary protein loss of 1.4 g tients reported in abstract form, the median age was 55
per day was alive and well at 29 months [89]. The second years, and the older patients received 100 to 140 mg/m2
patient received a transplant from an HLA-identical sis- melphalan. The three-month treatment-related mortal-
ter, and the nephrotic syndrome responded with a de- ity was 15%. Patients with predominant cardiac involve-
crease in urinary protein from 9.15 g to 1.3 g per day ment had a survival of 33% [95]. The reported rate of
with eradication of immunoglobulin light chains from the complete hematologic response was 55%.
urine. The patient was alive 18 months post-transplan- Among the first 20 stem cell transplant recipients at
tation [90]. Both patients had only single organ involve- Mayo Clinic, there was an impressive degree of morbid-
ment with amyloid. The restrictions currently applied to ity and mortality [96]. Stem cells were collected from
22 patients between January 1996 and September 1998.allogeneic transplant—those of age, good performance
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Three patients did not receive transplants after collection patients received transplants: 18 conditioned with mel-
owing to poor performance status. Two of the three died phalan alone and 3 with melphalan plus total body irradi-
of progressive amyloid at one and three months, and one ation. The mortality rate from toxic reactions was 43%:
patient was alive on dialysis one year after collection. 9 of 21 died within 30 days post-transplant. Ten of the 12
Stem cells were initially collected after priming with cy- survivors achieved a response. All deaths were a conse-
clophosphamide (3 g/m2) followed by colony-stimulating quence of multiorgan failure. There was significant selec-
factors (5 g/kg per day). Subsequent data analysis sug- tion of patients because the median time from diagnosis
gested that the morbidity associated with chemotherapy- to conditioning was 11 months and one patient received
primed mobilization was greater than that seen with a transplant 20 months after the diagnosis. The median
growth factor alone, and currently all patients are mobi- survival for all patients with amyloidosis is approxi-
lized by using 10g/kg of granulocyte colony-stimulating mately one year. This group is apparently self-selected
factor per day, with apheresis commencing on day plus 5. because they survived to the time of transplantation. In
We also have seen a mobilization-related death due to this report, patients presenting with two or more clinical
noncardiogenic pulmonary edema. While this toxicity manifestations had a four-year survival of 11%. Treat-
appears to be unique to amyloidosis, we have not had ment-related mortality exceeded 75% when more than
a fatal event in mobilizing patients with multiple mye- two organs were involved at the time of transplantation.
loma in more than 200 mobilization procedures [97]. Clearly, careful patient selection is necessary before pa-
Renal amyloidosis was present in 13 of the patients tients are accepted into a transplantation program.
who ultimately received transplants; 6 had echocardio- The development of post-transplantation multiorgan
graphic evidence of amyloid. Seven of the 19 patients who failure and severe gastrointestinal tract bleeding appears
received transplants have died, and four of them died to be the result of underlying amyloidosis because this
before day 100: two of pneumonia, one of multiorgan is not seen in transplantation for other indications. The
failure, and one of sudden cardiac death with autopsy mucositis that follows conditioning exposes amyloid-
evidence of severe cardiac amyloid. Two patients who involved vessels that readily rupture, and this leads to
survived subsequently died of progressive cardiac amy- serious hemorrhage. We have seen 9 of our 66 transplant
loid at seven and nine months. Twelve of the first 22 patients require dialysis support during the transplanta-
patients receiving stem cell transplants are alive with a tion procedure. Eight of the 9 had renal amyloid ne-
median follow-up of 18 months, and nine had objective phrotic syndrome before transplantation. Only 2 of the 9
evidence of responses. Six of these patients had renal survived the procedure. Others have reported acute tu-
amyloid. Remarkably, three of the responses took more mor lysis syndrome [99] after conditioning in amyloid
than nine months, including two patients who did not associated with renal failure, encephalopathy [100], se-
show a 50% reduction of proteinuria until at least 30 vere respiratory depression as a consequence of amyloid
months post-transplantation. This is consistent with the cardiomyopathy [101], and intestinal perforation on day
long time required for the body to mobilize and catabo- plus 4 after stem cell transplantation [102].
lize deposits of amyloid. A high incidence of gastrointes- Despite the reported toxicities, resolution of amyloid
tinal tract bleeding was seen as nearly 20% of the patients nephrotic syndrome has been reported after stem cell
had serious intestinal tract hemorrhage. The presumed transplantation [103]. Regression of amyloid hepatomeg-
etiology is amyloid deposits in the microvessels of the in- aly, reduced soft tissue infiltration of amyloid [104], and
testinal tract that rupture after the denuding of the intes- regression of autonomic dysfunction and coagulation fac-
tinal mucosa that occurs following high-dose chemother- tor deficiency have been reported as well [105], with
apy conditioning. Mortality was directly related to the resultant reversal of hemorrhage.
number of organ systems involved pretransplant; 9 of In another series, 22 patients with dominant renal in-
the 10 transplant recipients with only one organ system in-
volvement with AL were reported. Ten were treated with
volved are alive compared with 4 of the 7 patients surviv-
low-dose melphalan and prednisone. There was no sig-ing with two organ systems involved and none of 3 with
nificant clinical improvement and a median survival ofthree organ systems involved. Currently, we have com-
12 months. Three patients were treated with stem cellpleted 68 amyloid peripheral blood stem cell transplants.
transplantation. One died of treatment-related infectionTreatment-related mortality was 13%. A multicenter trial
during the neutropenic phase and the other two achievedof transplantation for amyloidosis has been completed
remissions and were symptom free at 12 and 18 monthsby the Eastern Cooperative Oncology Group, but as yet
post-transplant [106]. Caution does need to be exercised,the results have not been reported.
however, in patients with cardiac involvement with amy-
loid. Nine patients with cardiac amyloid were considered
TOXICITY OF TRANSPLANTATION candidates for stem cell transplants. Three died during
mobilization and six went on to receive stem cell trans-The first multicenter survey on the outcome of trans-
plantation for AL was published in 1998 [98]. Twenty-one plants. Three of the remaining six died of treatment-
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related causes. Three survived transplantation but one arial median survival in transplant recipients cannot be
determined accurately. Current protocols focus on re-died within six weeks. Of an original cohort of 11 patients,
only two were long-term survivors, suggesting that stan- ducing the dose of melphalan in an effort to reduce toxic
response rates while maintaining the higher responsedard transplantation conditioning is to be avoided in
patients with significant cardiac amyloidosis [107]. rates seen in transplant recipients. A proposed Eastern
Cooperative Oncology Group study plans a dose-escala-
tion scheme to determine the optimal dose of melphalan
CONVENTIONAL TREATMENT OF
for patients with AL.
YOUNGER PATIENTS
Patients receiving transplants for AL are selected by
CONCLUSIONvirtue of age, performance status, number of organs in-
volved, and absence of important cardiac involvement. Amyloidosis is a common cause of nephrotic syn-
drome in nondiabetic adults. All patients with nephroticIt is important to have some sense of what the survival
of a comparable control group would be. One would syndrome should have immunofixation of serum and
urine as part of their initial evaluation. The finding of aspeculate that it would be greater than the median sur-
vival of 13 months that has been reported for all patients light chain should redirect the evaluation toward ob-
taining specimens from bone marrow biopsy and subcu-seen with AL. A review of the Mayo Clinic experience
from 1983 to 1997 was performed to select patients eligi- taneous fat aspirate for amyloid stains. This obviates the
need for a kidney biopsy in nearly 90% of patients.ble for stem cell transplantation [108]. The criteria in-
cluded symptomatic disease, absence of multiple mye- Although previously unresponsive to therapy, many new
therapeutic options are available for the management ofloma, age younger than 70 years, a septal thickness less
than or equal to 15 mm, an ejection fraction greater than patients with AL and the disorder should not be consid-
ered one for which no therapeutic options exist.55%, and a creatinine concentration less than 2 mg/dL.
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